Opioid Epidemic Spurs Increase in Drug Testing, Risks for Employers
Ballard Spahr attorney Louis Chodoff (LAW ’88) discusses the impact of the opioid epidemic on employer drug testing policies.
Ballard Spahr attorney Louis Chodoff (LAW ’88) discusses the impact of the opioid epidemic on employer drug testing policies.
Harvey M. Katz (LLM ’82, BA ’73) discusses how closely held businesses can effectively fund and use buy-sell arrangements.
Nancy Conrad (LAW ‘89) and Tanya Salgado discuss hostile work environment claims in today’s workplace
Lauren E. O’Donnell (LAW ’09) discusses the importance of carefully handling whistleblower allegations.
Barbara T. Sicalides (LAW ‘89) highlights a DOJ and FTC report that details how to avoid antitrust lawsuits in job markets
Pennsylvania has joined the 23 states plus the District of Columbia that allow or soon will allow certain individuals to use medical marijuana. While the Medical Marijuana Act (the “Act”) will not be fully implemented for 18 months or more, it will pose a number of challenges for employers. It is therefore critical that employers
Wage-and-hour actions under the Fair Labor Standards Act (“FLSA”) are one of the largest growing types of litigation, and have been for over a decade. Pennsylvania businesses may soon experience an increase in FLSA-related litigation, as the Pennsylvania Department of Labor & Industry (DLI) and the U.S. Department of Labor (DOL) signed a “Memorandum of
At the February meeting of the American Bar Association’s House of Delegates in San Diego, which I attended, the delegates adopted a resolution giving states a regulatory framework for allowing non-lawyers to provide certain legal services. Resolution 105, sponsored by the ABA’s Commission on the Future of the Legal Profession, was purportedly aimed at addressing
This past fall, David Price, a 30-year-old free agent, signed a seven-year contract with the Boston Red Sox worth $217 million. Less than a week later, Zach Greinke, a 32-year old free agent, signed a six-year contract with the Arizona Diamondbacks worth $206 million. Despite these astronomical contracts, I argue in a forthcoming paper in